Four manuscripts of out 51 published last year on the topics of bladder, pancreatic, colorectal and skin cancer were chosen by the Alliance for Clinical Trials in Oncology Publications Committee as the most significant of the year. https://bit.ly/Top4-2025 NEJM.org #jnci #jco #NCI #clinicaltrials

New research on older survivors of #cancer shows late cardiovascular disease #CVD is common and mainly driven by age + prior heart risk, not cancer treatment. Results highlight value of cancer-agnostic approaches to predict risk of CVD.
academic.oup.com/jnci/advance...
@carygross.bsky.social #JNCI

International perspectives on exercise oncology highlights progress, challenges, & opportunities to expand access to exercise in cancer care worldwide #JNCI

@paulobergerot.bsky.social

academic.oup.com/jncimono/art...

Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer AbstractBackground. Most patients with metastatic breast cancer (MBC) are eligible for treatment with trastuzumab deruxtecan (T-DXd). No data are available

In metastatic #breastcancer, sacituzumab govitecan given after trastuzumab deruxtecan was linked to ⬇️ PFS across all subtypes. Real-world data published in #JNCI show differences in outcomes by type. academic.oup.com/jnci/advance...
@maryamlustberg.bsky.social

Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study Women treated for breast cancer (BC) often suffer genitourinary syndrome of menopause. These symptoms may be alleviated by vaginal estrogen therapy (VET) or menopausal hormone therapy (MHT). However, ...

Fair critique.

Smaller cohort but longer follow up in this #JNCI paper:

pmc.ncbi.nlm.nih.gov/articles/PMC...